Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Open-label Safety Study of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
2020-004885-21Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability of ELX/TEZ/IVA. Started Aug 2021; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2020-004885-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004885-21.